BR112023000817A2 - Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo - Google Patents
Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmoInfo
- Publication number
- BR112023000817A2 BR112023000817A2 BR112023000817A BR112023000817A BR112023000817A2 BR 112023000817 A2 BR112023000817 A2 BR 112023000817A2 BR 112023000817 A BR112023000817 A BR 112023000817A BR 112023000817 A BR112023000817 A BR 112023000817A BR 112023000817 A2 BR112023000817 A2 BR 112023000817A2
- Authority
- BR
- Brazil
- Prior art keywords
- same
- medical use
- preparation
- derivative
- containing sulfur
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DERIVADO DE ISOINDOLINA CONTENDO ENXOFRE, E MÉTODO DE PREPARAÇÃO DO MESMO E USO MÉDICO DO MESMO. A presente invenção refere-se a um derivado de isoindolina contendo enxofre, e um método de preparação do mesmo e uso médico do mesmo. Em particular, a presente invenção refere-se a um derivado de isoindalina contendo enxofre como representado pela fórmula geral (I), um método de preparação do mesmo, uma composição farmacêutica contendo o derivado, e uso do mesmo como um agente terapêutico, particularmente o uso do mesmo como um modulador de Cereblon no campo de tratamento de mieloma múltiplo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696995 | 2020-07-20 | ||
| CN202010783483 | 2020-08-06 | ||
| CN202011223930 | 2020-11-05 | ||
| CN202110410441 | 2021-04-16 | ||
| PCT/CN2021/107297 WO2022017365A1 (zh) | 2020-07-20 | 2021-07-20 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023000817A2 true BR112023000817A2 (pt) | 2023-02-07 |
Family
ID=79728998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000817A BR112023000817A2 (pt) | 2020-07-20 | 2021-07-20 | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230257366A1 (pt) |
| EP (1) | EP4183781A4 (pt) |
| JP (1) | JP2023534528A (pt) |
| KR (1) | KR20230042057A (pt) |
| CN (1) | CN115916768A (pt) |
| AU (1) | AU2021314401A1 (pt) |
| BR (1) | BR112023000817A2 (pt) |
| CA (1) | CA3184711A1 (pt) |
| MX (1) | MX2023000868A (pt) |
| TW (1) | TW202214594A (pt) |
| WO (1) | WO2022017365A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023138647A1 (zh) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 一种含硫异吲哚啉类衍生物的晶型 |
| US20240158370A1 (en) | 2022-09-09 | 2024-05-16 | Innovo Therapeutics, Inc. | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| WO2006058008A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
| JP2010522170A (ja) * | 2007-03-20 | 2010-07-01 | セルジーン コーポレイション | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN113788818A (zh) * | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| EP3381474A1 (en) * | 2017-03-27 | 2018-10-03 | Alfasigma S.p.A. | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| TWI830576B (zh) * | 2017-07-10 | 2024-01-21 | 美商西建公司 | 抗增生化合物及其使用方法 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| CN112492874A (zh) * | 2018-05-23 | 2021-03-12 | 细胞基因公司 | 治疗多发性骨髓瘤以及生物标志物对于4-(4-(4-(((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-4-基)氧基)甲基)苄基)哌嗪-1-基)-3-氟苄腈的用途 |
| EP3862348A4 (en) | 2018-09-30 | 2022-06-22 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, PROCESS OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| JP2022548775A (ja) * | 2019-09-19 | 2022-11-21 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | スピロ環式アンドロゲン受容体タンパク質分解剤 |
-
2021
- 2021-07-20 KR KR1020237005618A patent/KR20230042057A/ko unknown
- 2021-07-20 JP JP2023503463A patent/JP2023534528A/ja active Pending
- 2021-07-20 CN CN202180041057.4A patent/CN115916768A/zh active Pending
- 2021-07-20 BR BR112023000817A patent/BR112023000817A2/pt unknown
- 2021-07-20 TW TW110126626A patent/TW202214594A/zh unknown
- 2021-07-20 AU AU2021314401A patent/AU2021314401A1/en active Pending
- 2021-07-20 MX MX2023000868A patent/MX2023000868A/es unknown
- 2021-07-20 CA CA3184711A patent/CA3184711A1/en active Pending
- 2021-07-20 US US18/017,388 patent/US20230257366A1/en active Pending
- 2021-07-20 EP EP21847148.0A patent/EP4183781A4/en active Pending
- 2021-07-20 WO PCT/CN2021/107297 patent/WO2022017365A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP4183781A1 (en) | 2023-05-24 |
| WO2022017365A1 (zh) | 2022-01-27 |
| AU2021314401A1 (en) | 2023-03-09 |
| TW202214594A (zh) | 2022-04-16 |
| EP4183781A4 (en) | 2024-01-03 |
| MX2023000868A (es) | 2023-02-22 |
| KR20230042057A (ko) | 2023-03-27 |
| JP2023534528A (ja) | 2023-08-09 |
| CA3184711A1 (en) | 2022-01-27 |
| US20230257366A1 (en) | 2023-08-17 |
| CN115916768A (zh) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| BR112021018924A2 (pt) | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112023000817A2 (pt) | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo | |
| EA201490512A1 (ru) | Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека | |
| WO2014100071A3 (en) | Substituted pyrrolopyrimidines as hdm2 inhibitors | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| EA201490864A1 (ru) | Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов | |
| BR112015006828A2 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1 | |
| EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| BR112019000356A2 (pt) | compostos e métodos para modulação de smn2 | |
| EP4327886A3 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| BR112013028786A2 (pt) | método e composição de tratamento de sementes | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
| BR112017023164A2 (pt) | composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo |